North America Animal Parasiticides Market

North America Animal Parasiticides Market Size (2022 to 2027)

The size of the North America Animal Parasiticides Market has been calculated at USD 2.29 billion in 2022. It is forecasted to be growing at a CAGR of 5.7% and worth USD 3.03 billion by 2027.

The market shows a decent amount of potential for growth during the forecasting period. It is expected to expand with the development of animal healthcare. Animal parasiticides are the medicines used for animals to eradicate the parasites present on animals. These substances generally stay inert and are formed by mixing different ingredients with each other. Most ingredients in a parasiticide have similar kind of chemical structures and thus have many common characteristics in them. They are often grouped according to their chemical structure. The animal parasiticides are regarded as very important for the protection of animals from parasitic diseases.

An increase in spending on the healthcare of animals, increasing population with pet animals and growing concern for animal products are considered to be the driving factors for the growth of the North America Animal Parasiticides market.

However, the increased popularity of vegetarian and vegan lifestyles combined with strict restrictions on the sanctioning of animal parasiticides are some constraints for the growth of the North America animal parasiticides market.

This research report on the North America Animal Parasiticides Market has been segmented and sub-segmented into the following categories:

By Product: 

• Ectoparasiticides
• Endoparasiticides

By Animal type: 

• Food-producing Animals
• Companion Animals

By Country: 

• The United States
• Canada
• Rest of North America

Some of the major companies dominating the North America animal parasiticides market profiled in the report are Sanofi S.A. (Merial), Ceva Sante Animale, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc.